Eriodictyol
CAS 552-58-9
Eriodictyol (CAS 552-58-9) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 35028.566 nM | 19 | - |
| - | EC50 | 22736.666666666668 nM | 6 | - |
| - | Ki | 4021.6400000000003 nM | 5 | - |
| - | IC50 | 29.825 ug.mL-1 | 4 | - |
| - | MIC | 272.6666666666667 ug.mL-1 | 3 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Eriodictyol used for in pharmaceutical contexts?
Eriodictyol (CAS 552-58-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Eriodictyol?
No adverse-event association or SIDER side-effect rows are rendered for Eriodictyol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Eriodictyol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Eriodictyol with EU status "permitted".
What clinical phase is Eriodictyol in?
No phase 1-4 clinical development badge is rendered for Eriodictyol because the matched compound identifier rows do not contain a max-phase value.